Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

This study proposes to prove that the efficacy of adjuvant endocrine therapy for the premenopausal HR positive breast cancer patients is non-inferiority to adjuvant chemotherapy assessed by ultrasound response rate.

Trial Details

NCT ID
NCT02535221
Phase
PHASE3
Sponsor
Peking University
Status
RECRUITING
Cancer Type
HER2 Negative Breast Cancer
Interventions
  • Goserelin+TAM+AI
  • Epirubicin+CTX+5-Fu
Locations (sample)
  • Beijing, China|39.9075,116.39723

Key Eligibility Criteria

  • 35 years old \<age≤55 years old, in premenopausal status(with the judgement by researchers when the patients are recruited) Histologically confirme…
  • Stage: T2N0M0(cT\>2cm, SLNB negative), hard to proceed the breast conserving surgery(not feasible or may affect the appearance of breast)
  • Histologically confirmed HR+ (ER or PR positive, and \>50% cell in IHC) HER2 negative breast cancer by pathological evaluation
  • No other previous treatment for primary breast cancer

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Negative Breast Cancer Trials on Trialify →